Clinical Effects of Limosilactobacillus Reuteri Probiotics as an Adjunct to the Treatment of Periodontitis

Launched by UNIVERSIDADE DO PORTO · Feb 15, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a probiotic lozenge containing Limosilactobacillus reuteri, which is a type of beneficial bacteria, alongside standard non-surgical treatment for chronic periodontitis, a serious gum disease. The goal is to see if this probiotic can help improve the condition of patients with stage II, grade A, B, or C generalized periodontitis, which means they have significant gum issues that affect multiple areas of their mouth.

To participate in the study, you need to be at least 18 years old and diagnosed with generalized periodontitis. You should have at least three natural teeth in each part of your mouth. However, if you have had any periodontal treatment in the last two months, are pregnant or breastfeeding, or have certain health conditions like diabetes or immune system issues, you may not be eligible. If you join the study, you can expect to receive the probiotic lozenge along with your usual treatment and help researchers understand how well this new addition works for improving gum health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Patients over 18 years old, who intend to voluntarily participate in the study and:
• • Have a definitive diagnosis of stage II, grade A, B or C, generalized periodontitis (2018, World Workshop);
• • Have at least 3 natural teeth maintained per quadrant.
• Exclusion Criteria:
• • • Patients unable to understand the instructions necessary to participate in the study or unable to give informed consent;
• • Patients who have received any type of periodontal treatment 2 months prior to the start of study participation;
• • Pregnant or breastfeeding patients;
• • Patients with associated systemic pathology, such as diabetes, HIV, asthma, hyperthyroidism, immune system pathologies, lichen erosive or other pathologies treated with corticosteroids or immunosuppressants;
• • Patients undergoing therapy with drugs that may interfere with the response of the gingival tissues: anti-inflammatory drugs, anticonvulsants (phenytoin and sodium valproate), immunosuppressants (cyclosporin-A and tacrolimus) and antihypertensives (nifedipine and verapamil hydrochloride);
• • Patients undergoing anticoagulant therapy;
• • Patients allergic to both lidocaine, articaine and mepivacaine;
• • Patients who require antibiotic prophylaxis for bacterial endocarditis;
• • Patients who have had antibiotic therapy within 2 months of study participation;
• • Patients using chlorhexidine, or other mouthwashes or elixirs;
• • Patients undergoing orthodontic treatment.